Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;25(8):1352-1360.
doi: 10.1002/ejhf.2884. Epub 2023 Jun 7.

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

Domingo A Pascual-Figal  1   2   3   4 , J Luis Zamorano  4   5 , Mar Domingo  6 , Herminio Morillas  7 , Julio Nuñez  4   8 , Marta Cobo Marcos  4   9 , Alejandro Riquelme-Pérez  2   4 , Albert Teis  6 , Enrique Santas  8 , Cesar Caro-Martinez  1 , Jose Manuel Pinilla  10 , Jose F Rodriguez-Palomares  4   11 , David Dobarro  4   12 , M Alejandra Restrepo-Córdoba  13 , J Ramón González-Juanatey  4   14 , Antoni Bayés Genís  4   6 ; DAPA-MODA Study Investigators
Collaborators, Affiliations
Free article

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

Domingo A Pascual-Figal et al. Eur J Heart Fail. 2023 Aug.
Free article

Abstract

Aims: Dapagliflozin improves the prognosis of patients with heart failure (HF), regardless of left ventricular ejection fraction (LVEF). However, its effect on cardiac remodelling parameters, specifically left atrial (LA) remodelling, is not well established.

Methods and results: The DAPA-MODA trial (NCT04707352) is a multicentre, single-arm, open-label, prospective and interventional study that aimed to evaluate the effect of dapagliflozin on cardiac remodelling parameters over 6 months. Patients with stable chronic HF receiving optimized guideline-directed therapy, except for any sodium-glucose cotransporter 2 inhibitor, were included. Echocardiography was performed at baseline, 30 and 180 days, and analysed by a central core-lab in a blinded manner to both patient and time. The primary endpoint was the change in maximal LA volume index (LAVI). A total of 162 patients (64.2% men, 70.5 ± 10.6 years, 52% LVEF >40%) were included in the study. At baseline, LA dilatation was observed (LAVI 48.1 ± 22.6 ml/m2 ) and LA parameters were similar between LVEF-based phenotypes (≤40% vs. >40%). LAVI showed a significant reduction at 180 days (-6.6% [95% confidence interval -11.1, -1.8], p = 0.008), primarily due to a decrease in reservoir volume (-13.8% [95% confidence interval -22.5, -4], p = 0.007). Left ventricular geometry improved with significant reductions in left ventricular mass index (-13.9% [95% confidence interval -18.7, -8.7], p < 0.001), end-diastolic volume (-8.0% [95% confidence interval -11.6, -4.2], p < 0.001) and end-systolic volume (-11.9% [95% confidence interval -16.7, -6.8], p < 0.001) at 180 days. N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed a significant reduction at 180 days (-18.2% [95% confidence interval -27.1, -8.2], p < 0.001), without changes in filling Doppler measures.

Conclusion: Dapagliflozin administration in stable out-setting patients with chronic HF and optimized therapy results in global reverse remodelling of cardiac structure, including reductions in LA volumes and improvement in left ventricular geometry and NT-proBNP concentrations.

Keywords: Biomarkers; Dapagliflozin; Heart failure; Left atrium; Remodelling.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956-1964. https://doi.org/10.1038/s41591-022-01971-4
    1. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516-525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186
    1. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132. https://doi.org/10.1186/s12933-018-0775-z
    1. Dhingra NK, Mistry N, Puar P, Verma R, Anker S, Mazer CD, et al. SGLT2 inhibitors and cardiac remodelling: A systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail. 2021;8:4693-4700. https://doi.org/10.1002/ehf2.13645
    1. Fan G, Guo DL. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials. Eur J Intern Med. 2023;114:49-57. https://doi.org/10.1016/j.ejim.2023.04.002

Publication types

Associated data